Johnson & Johnson
JNJ (NYSE)
Johnson & Johnson stands out as a top-rated healthcare giant with impressive one-year gains of 45.17%. The company boasts a solid dividend yield of 2.54%, making it an attractive option for investors seeking reliable income from financially healthy companies. Analysts have a consensus rating of "Moderate Buy," with a median price target of $211.00, reflecting confidence in its stable growth trajectory.
Pros:
- Established healthcare giant
- High one-year gains
Cons:
- Market competition
- Regulatory risks
Johnson & Johnson (JNJ) presents a compelling investment opportunity for those seeking a combination of growth potential and income through dividends, particularly appealing to conservative investors looking for stability in the healthcare sector. With strong recent performance and a moderate buy consensus among analysts, it may suit both income-focused investors and those looking for long-term capital appreciation.